Therefore, this study aims to investigate the anti-obesity and anti-diabetic effects of bioactive compounds derived from a <i>Meretrix lusoria</i> Protamex enzymatic hydrolysate (MLP) fraction (≤1 kDa) through a 6-week treatment (150 mg/kg or 300 mg/kg, administered once daily) in leptin receptor-deficient <i>db/db</i> mice. The gene discussed is LEPR; the disease is Obesity.